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Abstract
The fast kinetics and bioorthogonal nature of the tetrazine trans-cyclooctene (TCO) ligation 
makes it a unique tool for PET probe construction. In this study, we report the development of 
an 18F-labeling system based on a CF3-substituted diphenyl-s-tetrazine derivative with the aim of 
maintaining high reactivity while increasing in vivo stability. c(RGDyK) was tagged by a CF3-
substituted diphenyl-s-tetrazine derivative via EDC-mediated coupling. The resulting tetrazine-
RGD conjugate was combined with a 19F-labeled TCO derivative to give HPLC standards. The 
analogous 18F-labeled TCO derivative was combined with the diphenyl-s-tetrazine-RGD at μM 
concentration. The resulting tracer was subjected to in vivo metabolic stability assessment, and 
microPET studies in murine U87MG xenograft models. The diphenyl-s-tetrazine-RGD combines 
with an 18F-labeled TCO in high yields (>97% decay-corrected on the basis of TCO) using only 4 
equiv of tetrazine-RGD relative to the 18F-labeled TCO (concentration calculated based on 
product’s specific activity). The radiochemical purity of the 18F-RGD peptides was >95% and the 
specific activity was 111 GBq/μmol. Noninvasive microPET experiments demonstrated that 18F-
RGD had integrin-specific tumor uptake in subcutaneous U87MG glioma. In vivo metabolic 
stability of 18F-RGD in blood, urine and major organs showed two major peaks: one corresponded 
to the Diels-Alder conjugate and the other was identified as the aromatized analog. A CF3-
substituted diphenyl-s-tetrazine displays excellent speed and efficiency in 18F-PET probe 
construction, providing nearly quantitative 18F labeling within minutes at low micromolar 
concentrations. The resulting conjugates display improved in vivo metabolic stability relative to 
our previously described system.
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Positron emission tomography (PET) is a powerful and highly sensitive imaging technology 
with the capacity to observe metabolic processes and track radiolabeled biomolecules in 
vivo.1 Of the various positron emitting radionuclides, 18F finds most extensive use due to its 
clinically attractive half-life (t1/2 = 110 min) and high positron efficiency (β+ = 99%). To 
date, clinical applications of PET have largely involved small molecule probes such 
as 18F-2-deoxy-2-fluoroglucose.2, 3 Currently, there is great interest in the development of 
peptidic and protein-based probes for 18F PET imaging, with a correlated need to develop 
methods for bioligand probe construction. New methods for probe construction must operate 
efficiently within the constraints of 18F-labeling chemistry, which include the limited 
nucleophilicity and short half-life of fluoride and the need to efficiently conjugate molecules 
at low concentrations relevant to radiochemical experimentation.
A variety of 18F-labeled synthons have been developed and successfully applied to a host of 
peptides and proteins for 18F-PET probe construction. The utility of many 18F PET probes is 
hindered by multistep probe syntheses where 18F is carried through multiple chemical 
intermediates—a major limitation given the technically demanding nature of 18F 
radiochemistry. For the conjugation of 18F to the biological ligand, peptides or proteins are 
often used in large excess in order to obtain reasonable yields for 18F attachment. 
Additionally, 18F-tagged proteins or large-peptides are often inseparable from their 
unlabeled precursors which can compromise the signal through competitive inhibition and 
result in low specific activity. Furthermore, sacrificing milligram quantities for labeling 
reactions is impractical for peptides or proteins that are not available in large quantity. 
Greatly needed are efficient and robust methods for labeling proteins and peptides by 18F at 
low concentrations.
In 2008, we described methods for synthesizing trans-cyclooctene derivatives4 and applying 
them in fast bioorthogonal reactions with tetrazines.5 With strained TCO derivatives, rate 
constants of k2 > 106 M−1s−1 have been measured.6–9 Contemporaneous with the initial 
study of TCO, several groups described reactions of tetrazines with derivatives of 
norbornene10 or the Reppe anhydride,11 with a measured rate constant of k2 = 1.9 M−1s−1 at 
20 °C in PBS for norbornene conjugation. Recently, cyclopropenes,12, 13 
cyclooctynes,6, 14, 15 and terminal alkenes16 have also been used as dienophiles for tetrazine 
ligation. While each of these dienophiles offers complementary advantages, TCO 
derivatives display the fastest rate constants.
The tetrazine-TCO ligation has become broadly used for research in nuclear medicine 
including applications in pretargeted imaging,17–19 and studies have been directed toward 
optimizing and improving the pharmacokinetics and pharmacodynamics for systems based 
on dipyridyl-s-tetrazine and monoaryltetrazines.7, 17–25 In 2010, Robillard first showed that 
the tetrazine ligation method could be applied in a pre-targeted antibody using single photon 
emission computed tomography (SPECT).23 More recently, Robillard has described factors 
that contribute to the in vivo stability of TCO’s toward isomerization,7 and clearing agents 
have been developed that improve tumor-to-blood (125 fold) ratios.22 Weissleder has shown 
that polymer modified tetrazines can be used for in vivo bioorthogonal labeling and PET 
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imaging using an 18F-labeled TCO derivative.20 More recently, Weissleder and Lewis 
reported a pretargeting approach for PET imaging based on this method and demonstrated 
dramatically reduced nontargeted organ uptake.24 Recently, the reaction of a 11C-labeled 
tetrazine with a TCO derivative was described,26 and Kuntner and Mikula described the 
development of a 18F-labeled tetrazine with favorable pharmacokinetic properties.25
In 2010, we developed a radiolabeling method for bioconjugation based on the Diels-Alder 
reaction between dipyridyl-s-tetrazines and an 18F-labeled trans-cyclooctene.27 As shown in 
Figure 1, 18F-labeled TCO 2 could be obtained in high radiochemical yield (71%) by 
combining nosylate 1 with 18F-fluoride (100 mCi). 18F-2 is an effective reagent for 
creating 18F-labeled probes within seconds at low micromolar concentrations, and we have 
used this reagent to make cyclic RGD (cRGD) and VEGF protein conjugates for cancer 
imaging28, 29 and exendin-4 conjugates for applications in insulinoma imaging and diabetes 
monitoring.30 Notably, these conjugates were synthesized without using a large excess of 
the peptidic labeling precursor (Figure 1b). Avoiding excess labeling precursor is critically 
important for proteins and large polypeptides such as exendin-4 (MW 4775), where the 
labeled and unlabeled peptide are not readily separable, and unlabeled peptide can 
significantly decrease signal due to competitive inhibition.30 Weissleder and Lewis have 
also used 18F-2 in a number of applications including a recent demonstration of pretargeted 
imaging.24
An important factor that has not received significant attention is the metabolic stability of 
tetrazine-TCO conjugates. Dipyridyl-s-tetrazine-based probes with good pharmacokinetic 
properties have been constructed through conjugation to large peptides (exendin-4)30 or by 
including PEG-spacers in antibody-pretargeting studies.7, 22, 23 We also described that 18F-
trans-cyclooctene 2 undergoes very rapid conjugation with a dipyridyl-s-tetrazine-cRGD 
construct, and the resulting isomeric conjugates 4b can be used to image tumors in mice 
(Fig. 1c). Here, a relatively high level of organ uptake in the liver and kidneys was observed, 
presumably due to the hydrophobic nature of the probe. Because of the high residence time 
in the liver, we expected that this system would provide a good platform to test and improve 
the metabolic stability of tetrazine-based probes. In our study on 4b, an attempt to re-isolate 
radioactive 4b from the major organs, urine and blood of a mouse was not unsuccessful, and 
only hydrophilic degradation products were observed by radio-HPLC analysis. We 
hypothesized that the imines of 4b, flanked with electron withdrawing pyridines, may be 
susceptible to nucleophilic attack and thereby provide a possible handle for degradation. We 
also hypothesized that a conjugate (Fig 1d) with less electron withdrawing aromatic groups 
would be more stable. Here, we describe a 3,6-diphenyl-s-tetrazine derivative that displays 
fast conjugation rates toward 18F-2 and gives conjugates with improved metabolic stability 
in an in vivo mouse study. 18F-labeling yields are discussed and the metabolic stability of 
the 18F-2 tagged cRGD conjugate is described. The PET probe was evaluated for integrin 
αvβ3 imaging in U87MG tumor-bearing mice by microPET.
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The CF3-substituted diphenyl-s-tetrazine 635 was prepared by an improved two-step 
procedure and elaborated by EDC coupling to cRGD derivative 7 (Fig. 2a) To gauge the 
reactivity of derivatives of diaryltetrazine 6, stopped flow kinetic analysis was used to 
measure the rate of the Diels-Alder reaction between tetrazine derivative 8 and equatorially 
substituted trans-cyclooctene derivative 9, the precursor to 18F-2 (Fig. 2). The 
undecaethylene glycol sidechain of 8 was added to enhance water solubility. In water/MeOH 
(6:4, v/v) at 25 °C, a second order rate constant k2 = 1000 ± 100 M−1s−1 was measured.
The cycloaddition reaction of tetrazine-cRGD 7 and 19F-2 provided 18F-cRGD conjugates 
10, which were used as radiolabeling standards and for the integrin receptor binding assay. 
Consistent with the high reactivity of 8, the pink color of tetrazine-cRGD 7 disappeared 
immediately upon mixing with 19F-2. The identity of the 19F-cRGD conjugates 10 were 
confirmed by LC-MS. As expected based from prior observation and a model study,5, 9, 36 
both aromatized conjugates 10b were formed in addition to dihydropyridazine conjugates 
10a (Fig. 3a,b). Collectively, we refer to the mixture of aromatic and dihydropyridazine 
conjugates as 10.
Radiochemistry
18F-labeled trans-cyclooctene (18F-2) was produced using the protocol developed in our 
laboratories,27 and utilized in radiolabeling experiments with tetrazine-cRGD derivative 7 
(Fig. 4). With only a 4-fold excess of 7 (4 μM) relative to 18F-2 (1 μM, calculated based on 
the specific activity of 18F-10a), a 97% radiochemical yield of 18F-10a was obtained (Fig. 
4b). The specific activity of 18F-10 was determined to be 3.0 ± 1.0 Ci/μmol after purification 
by comparing the UV absorption with standard titration curve.
Cell Integrin Receptor-Binding Assay
Receptor-binding affinity studies of 19F-10 and unmodified c(RGDyK) toward αvβ3 integrin 
were performed using αvβ3 integrin–positive U87MG cells. Binding on the cell membrane 
allows cross-linking and integrin receptor multimerization, through which multivalent 
binding and clustering of receptor is studied in the natural context of the integrin. We 
compared the receptor-binding affinity of 19F-10 with that of unlabeled c(RGDyK) by 
performing competitive displacement studies with 125I-echistatin (Fig. 3c). Both 19F-10 and 
unmodified c(RGDyK) peptides inhibited the binding of 125I-echistatin to αvβ3 integrin–
positive U87MG cells. The IC50 value for 19F-10 and c(RGDyK) was 39.8 ± 4.5 and 19.6 ± 
3.2 nmol/L, respectively. Thus, the fluoride incorporation via tetrazine ligation into the 
cRGD peptide had minimal effect on binding affinity to the αvβ3 receptors.
In vivo Metabolism of 18F-10
The metabolic stability of 18F-10 was determined in mouse blood, urine and in liver and 
kidney homogenates at 2 h after tracer injection. The extraction efficiency of all organs was 
between 56% and 98%. The lowest extraction efficiency was found for the kidney 
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homogenates and the highest extraction efficiency was from blood sample. The intact probes 
were 75%, 51%, 57%, and 62% for blood, kidney, liver, and urine samples respectively (Fig. 
5). The major metabolites correlate well with the aromatized product. These results showed 
that the new probe displayed significantly higher stability than previous dipyridyl 
analogs.27, 29
microPET Studies
The localization of 18F-10 in human U87MG tumor-bearing nude mice (n = 5) was 
performed by multiple time-point static microPET scans. Figure 6a shows microPET images 
of a female mouse at different times after injection of 7.4 MBq (200 μCi) of 18F-10. All 
microPET images were decay corrected. The tumor was clearly visualized with good 
contrast. Fig. 6b shows the microPET images with a blocking dose of unlabeled c(RGDyK) 
peptide coinjection. The tumor uptake of the radio probe was clearly reduced. The 
microPET imaging study demonstrated high and specific binding of 18F-10 to human 
U87MG tumors. Quantification of activity accumulation in the tumor and major organs (Fig. 
6c) was determined by biodistribution studies conducted 2 h post injection.
DISCUSSION
Although dipyridyl-s-tetrazine conjugates with 18F-2 can be created rapidly and efficiently, 
in prior studies on RGD-based imaging29 we observed that these conjugates have only 
moderate metabolic stability in vivo. We hypothesized that a conjugate with less electron 
withdrawing phenyl groups would be more stable, and in line with prior observations may 
spontaneously oxidize to give aromatic pyridazine products that are also highly stable.5, 9 To 
test this hypothesis, we prepared the diphenyl-s-tetrazine derivatives 7 and 8 from precursor 
6. Compound 8 reacts with trans-cyclooctene derivative 9 in water/MeOH (6:4, v/v) at 25 
°C with k2 = 1000 ± 100 M−1 s−1. When compared under similar conditions, the rate of 
reactivity for the CF3-substititued tetrazine 8 falls within an order of reactivity of the faster 
dipyridyl-s-tetrazine derivatives 3.6, 37
Encouraged by the efficient reactivity of 8 with 9, we reacted the cRGD-diphenyl-s-tetrazine 
derivative 7 with 19F-2 to provide conjugate 10a, a mixture of isomers (Fig. 3a). In line with 
observations from model compounds,36 we found that 10a partially oxidized spontaneously 
in solution to provide aromatic 10b. Shown in Fig. 3b is the HPLC–MS trace of the Diels-
Alder conjugate from 7 (10 μM) and 19F–2 (10 μM) analyzed after standing overnight in 
aqueous solution. As expected,5, 9 in addition to peaks from the dihydroaromatic Diels-
Alder adducts 10a (m/z 1176), we also observed the aromatized pyridizine adducts 10b (m/z 
1178). As shown in Fig. 3c, the receptor-binding affinity of 10 was compared to that of 
unlabeled c(RGDyK) by performing competitive displacement studies with 125I-echistatin. 
The 19F-cRGD conjugate 10 was comparable to the unlabeled cyclic RGD peptide in the 
ability to inhibit the binding of 125I-echistatin to αvβ3 integrin–positive U87MG cells.
To study the stability of the 18F-labeled Diels-Alder conjugates, an in vivo metabolic study 
was carried out by injecting 18F-10 into an athymic nude mouse that was sacrificed 2 h post 
injection. The organ uptake by the kidneys and liver for 18F-10 (Fig. 6) is similar to what 
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was observed with dipyridyl-s-tetrazine-RGD construct 4b (Fig. 1c). As shown previously, 
the organ uptake was greatly reduced when the more hydrophilic probe 4a based on the 
exendin-4 ligand (Fig. 1b) was used to image a GLP-1R positive tumor in mice.30 Similarly, 
we anticipate that the pharmacokinetic/pharmacodynamic properties of probes related to 4a 
will readily be improved with protein-based probes, or with peptide-based probes where 
hydrophilic spacer molecules are employed. For the present study to investigate the stability 
of the tetrazine-TCO conjugate in vivo, the organ uptake of 18F-10 was considered 
advantageous as it allowed study of probe that had been retained in these organs. Thus, 
major tissues were collected and homogenized, and the activity was extracted and analyzed 
by HPLC (Fig. 5). Fractions were collected each minute and radioactivity measured with the 
γ-counter. The average fraction of intact tracer was significantly improved relative to the 
first generation system 4b (Fig. 1c), where only degradation products were observed by 
HPLC in similar attempts to recover radioactivity from blood, urine and organs of the 
animal. For 18F-10, a hydrophilic byproduct was not observed by HPLC analysis, and the 
probe was detected with high fidelity in extracts from the kidneys, liver, blood and urine. To 
ensure that there was not a hydrophilic byproduct in the homogenates, we also analyzed the 
aqueous phase from the blood sample. The HPLC profile was very similar to that from the 
organic phase. In each of the metabolic extracts, two peaks were observed. Upon 
comparison of the HPLC data (Fig. 5) and LC/MS (Fig. 3b) data with cold conjugates it was 
concluded that one peak corresponded to the dihydropyridizine isomers of 18F-10a, and the 
other peak to the aromatized isomers 18F-10b. One limitation of using 18F-2 is the high 
number of isomeric conjugates that are formed upon conjugation with unsymmetrical 
tetrazines, which may present an issue for clinical translation. Efforts to ameliorate this issue 
by using higher symmetry cyclooctene derivatives are in progress.
18F-10 exhibited good metabolic stability in vivo, and injection of 18F-10 into a U87MG 
mouse model resulted in an effective method for αvβ3 imaging. The integrin αvβ3 receptor 
specificity was confirmed by blocking experiments, in which unlabeled cRGD was 
administered prior to the injection of the 18F-10 (Fig. 6). Thus, this labeling system has 
improved product stability, and no defluorination of 18F-10 was observed as no visible bone 
uptake was observed in any of the microPET scans. We also performed PBS stability study 
on newly synthesized 18F-10. Around 28% of product got aromatized at 2 h post incubation 
(Fig S2).
A major advantage of the tetrazine ligation lies in the ability to enable fast reactivity at low 
micromolar concentrations within minutes and without an excess of either reactant. After 
demonstrating that the tetrazine 7 is robust and that conjugates with 18F-2 have good 
stability in vivo, we explored the lower limit of concentration for the 18F labeling reaction. 
As benchmarks, the decay-corrected labeling yield was 35–45% when N-
succinimidyl-4-18F-fluorobenzoate was combined with an RGD derivative at 0.11 mM,38 
and 70% when an RGD derivative at 1.8 mM was labeled with 18F by Cu-catalyzed azide/
alkyne cycloaddition.39 By contrast, the tetrazine–TCO ligation reaction is nearly 
quantitative at a concentration that is more dilute by more than 3 orders of magnitude (Fig. 
4). Thus, a 97% radiochemical yield of 18F-10 was obtained in 5 minutes when 18F-2 (4 
μCi/μL, 1 μM) was combined with only 4 equiv. of 7 (0.4 μg, 0.4nmol, 4 μM). We believe 
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that this combination of fast reactivity to yield metabolically stable conjugates should 
continue to enable applications in 18F-based labeling and imaging.
CONCLUSION
A CF3-substituted 3,6-diphenyl-s-tetrazine derivative displays fast conjugation rates 
toward 18F-2, providing nearly quantitative 18F labeling was observed within minutes at low 
micromolar concentrations. This bioorthogonal ligation reaction was used to construct 
an 18F-cRGD conjugate, which was evaluated for integrin αvβ3 imaging in U87MG tumor-
bearing mice by microPET. The conjugate was further shown to display improved metabolic 
stability in an in vivo mouse study.
ASSOCIATED CONTENT
Experimental procedures, spectral data for all new compounds, kinetic plots, and HPLC 
traces. This material is available free of charge via the Internet at http://pubs.acs.org.
MATERIALS AND METHODS
All commercially available chemical reagents were used without further purification. The 
syringe filter and polyethersulfone membranes (pore size, 0.22 μm; diameter, 13 mm) were 
obtained from Nalge Nunc International (Rochester, NY). 125I-Echistatin was purchased 
from PerkinElmer (Piscataway, NJ). c(RGDyK) was obtained from Peptides International 
(Louisville, KY). All HPLC conditions are gradient. HPLC methods, NMR spectra and mass 
spectrometry details are listed in supplementary data. MicroPET scans were performed on a 
microPET R4 rodent model scanner (Siemens Medical Solutions USA, Inc., Knoxville, TN), 
or a GE eXplore Vista.
Chemistry
Detailed synthetic procedures and characterization details are provided as supporting 
material.
Stopped-flow kinetic analysis
The second order rate constant was measured under pseudo-first order conditions using an 
excess of TCO 9 by following the exponential decay of absorbance due to the tetrazine 
chromophore of 8 at 292 nm using an SX 18MV-R stopped-flow spectrophotometer 
(Applied Photophysics Ltd.). Thus, equal volumes of solutions of TCO 9 (0.50 mM, 1.0 mM 
or 2.0 mM in 60:40 water : methanol) and tetrazine 8 (0.050 mM in 60:40 water : methanol) 
were mixed in the stopped flow device. The final concentration of 8 was 25 μM, and 9 was 
0.25 mM, 0.50 mM or 1.0 mM. At each concentration, kinetic data was repeated nine times 
(triplicate runs on three independent samples) at 298 K. Thus, 27 rate measurements were 
made. The rate constant was determined by nonlinear regression analysis using Prism 
(GraphPad Software, Inc.). The mean second order rate constant under these conditions was 
measured to be 1000 +/− 100 M−1s−1.
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The 18F-labeled TCO (18F-2, Figure 1) was synthesized as reported.27 A solution of 0.4 mCi 
(14.8 MBq) 18F-2 in ethanol was added to different concentrations of tetrazine-cRGD 7 in 
DMSO (total volume 100 μL). After vigorous vortexing for 1 min at room temperature, the 
reaction was quenched with 1 mL 0.1% TFA in water and loaded onto a C-18 HPLC column 
to determine the labeling yield. With a loading of 7 at 4μM, probe 10 was obtained with 
97% labeling yield (Fig. 4). For small animal study, the HPLC fraction containing 18F-10 
was collected and the HPLC eluent was removed using a rotary evaporator. 18F-10 was 
reconstituted in 1 mL PBS and passed through a 0.22 μm syringe filter for animal injection.
Cell Integrin Receptor-Binding Assay
In vitro integrin-binding affinities and specificities of tetrazine-cRGD peptides were 
assessed via displacement cell binding assays using 125I-echistatin as the integrin-specific 
radioligand. Experiments were performed on the human glioblastoma U87MG cell line by 
modification of a method previously described.31
Animal Models
Animal procedures were performed according to a protocol approved by the UNC 
Institutional Animal Care and Use Committee. Human brain cancer carcinoma xenografts 
were induced by subcutaneous injection of 107 U87MG cells into the right front leg of 
female athymic nude mice. Three weeks after inoculation of the tumor cells, when the tumor 
reached 0.4–0.6 cm in diameter, the mice were used for microPET experiments.
Metabolic Stability
The metabolic stability of 18F-10 was evaluated in an athymic nude mouse bearing a 
U87MG tumor according a reported procedure.32 Detailed procedures are included as 
supplementary material.
microPET Studies
PET of tumor-bearing mice was performed on an eXplore Vista microPET/CT rodent model 
scanner using a reported method.33, 34 In brief, the mice were injected with 7.4 MBq of 18F-
RGD conjugate 10 with or without a blocking dose of unlabeled RGD peptide via the tail 
vein and then anesthetized with 2% isoflurane and placed near the center of the FOV of the 
microPET where the highest image resolution and sensitivity are obtained.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) Synthesis of 18F-TCO 2. (b) Rapid 18F-labeling of a 4.8 kDa peptide takes place rapidly 
at low concentration using only a 2-fold excess of the peptide precursor. (c) Probe 4b has 
been used to image U87MG tumors in mice. (d) A new probe that can also be constructed 
rapidly and used for U87MG tumor imaging in mice with the added benefit of improved 
metabolic stability.
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(a) Synthesis of a cRGD-diphenyl-s-tetrazine conjugate. (b) The rate of the conjugation of 8 
with 9 was determined by stopped-flow kinetic analysis. (c) The exponential plot of the 
reaction of 8 (25 μM) and 9 (1.0 mM) in 40:60 MeOH:water was monitored at 292 nm. Data 
was recorded for 20 s at 298 K, with triplicate runs on three independent samples at three 
different concentrations (27 runs total). (d) The average of three observed rates k′ vs 
concentration of 9 for the reaction between 8 and 9. Under these pseudo-first order 
conditions the second order rate constant (k2) was determined by nonlinear regression to be 
1000 +/− 100 M−1s−1.
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(a) Conjugation of a cyclic-RGD-tetrazine 7 with F-TCO 2 gives conjugates 10a, which 
slowly oxidize to aromatic isomers 10b under ambient conditions in aqueous solution. (b) 
LC/MS analysis of the Diels-Alder conjugate from 19F–2 acquired after the sample had been 
allowed to stand overnight shows a mixture of aromatized and more slowly eluting 
dihydroaromatic products. Chromatographic resolution was higher and retention times 
longer in this LC/MS run than in radio-HPLC analyses (Fig 4, 5). (c) Cell-binding assay of 
c(RGDyK) and 19F-Diels-Alder conjugates 10 using U87MG cells (integrin αvβ3-positive 
human glioblastoma). The cell-binding affinity of the peptides was determined by 
performing competitive displacement studies with 125I-echistatin (n = 3).
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18F labeling by 18F-2 (1 μM) with differing concentrations of 7. The product 18F-10a is a 
mixture of regioisomers. (a) HPLC standard of 18F-2. (b) 97% radiochemical yield with 4 
equiv of 2. The specific activity of 18F-10 was determined to be 3.0 ± 1.0 Ci/μmol after 
purification by comparing the UV absorption with standard titration curve.
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Metabolic stability of 18F-10 in mouse blood and urine samples and in liver, and kidney 
homogenates at 1 h after injection. Fractions were collected every minute and radioactivity 
measured by γ-counter. The radio-HPLC profile of 18F-10 standard is also shown. In each of 
the metabolic extracts, two peaks were observed. One peak corresponded to 
dihydropyridizine isomers 18F-10a, the other peak corresponded to isomers of 
pyridizine 18F-10b.
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microPET images of athymic nude mice bearing U87MG tumor at 0.5, 1, and 2 h after 
injection of 18F-10 (a) without or (b) with a blocking dose of c(RGDyK) peptide (10 mg/kg 
body weight) (n = 5). Tumors are indicated by arrows. (c) bio-distribution study of 18F-10 in 
nude mice bearing U87MG tumor at 2 h p.i..
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